• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Nazif Kürkçüolu, MD; Remzi Tandodu, MD
Turkish Health and Therapy Foundation Memorial Ahmet Örs Hospital Emek Ankara, Turkey

Arch Dermatol. 1990;126(6):831-832.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Cutaneous leishmaniasis is caused by Leishmania tropica and is prevalent in tropical and subtropical zones of the world.

The treatment may not always be satisfactory. Some cases may be refractory to chemotherapeutic agents, including pentavalent antimony drugs. In such cases, the persistence of the infection may be due to depression of antigen-specific cell-mediated immunity' and defects in macrophage functions.^2-4

We treated a patient with cutaneous leishmaniasis with a combination of interferon gamma and pentavalent antimony who failed to respond to two courses of methylglucamine antimonate (Glucantime) therapy previously.

The patient received recombinant human inferferon (RU 42369, Roussel-UCLAF, Romainville, France) injections daily in a dose of 100 µg/m² of body surface area. The dose of methylglucamine antimonate injections was 50 mg/kg per day. During the treatment, the following laboratory tests were performed: complete blood cell count with differential white blood cell count, urinalysis, and blood chemistry . . . [Full Text PDF of this Article]

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?